Company Overview
the ability of bisphopsphonate part of the molecule to deliver the conjugate to the site of bone
destruction (targeted delivery). The drug is quite
“Osteros Biomedica” is a private Russian biotech
stable to stay intact after intra venous administration
company founded in 2012 for the development and
until it releases both agents on the bone. Thus
commercialization of the drugs for the treatment of
released cytotoxic agent leads to the destruction of
bisphosphonate itself binds to hydroxyapatite
The first drug to be developed is MBC-11 compound
crystals in bone tissues and prevents its resorption.
- a synthetic chemical conjugate of two molecules: a
The main advantages of the drug: its high efficiency
bisphosphonate (providing bone affinity and
even at low dose, as well as the possibility of its use
preventing the destruction of the bone tissue) and a
in the adjuvant therapy. The effectiveness of MBC-
cytotoxic agent (destroying tumor cells). Extensive
11 in the mode of daily administration has been
preclinical studies and clinical trials in canine
patients demonstrated efficacy of MBC-11 in daily administration.
The Company is currently conducting additional
One of the areas of Company’s current research is
preclinical trials in order to initiate clinical trials in
the development of an improved drug product
formulation with increased stability in plasma and the potential to reduce the therapeutic dose, for
more comfortable use in the treatment of targeted
Metastases in the bone tissues often complicates the
course of breast cancer, prostate cancer, lung
cancer, kidney cancer and thyroid cancer. The share of these types of cancer in the world accounts for
The scientific team is led by Alexander Karpeisky
about 700,000 new cases per year. More than half
(USA), Ph.D. a former head of scientific research
of these patients have skeletal complications, that
group in Ribozyme Pharmaceuticals, Inc (acquired
result in patents’ sufferings (severe pain, pathologic
by Merk & Co) and Transgenomic Inc., is a co-
fractures, spinal cord compression), and also
author of 55 scientific articles and more than 40
considerably more expensive treatment: +$48 000
patents. The management of “Osteros Biomedica” is
represented by highly qualified specialists of the
Maxwell Biotech Group and the Russian biotech
The most favorable market segments for MBC-11,
are the treatment of multiple myeloma and metastatic cancer with bone localization. According
to the estimates, the volume of the target market in
Intellectual Property Status
Russia, the USA and EU countries amounts to $ 5.5 billion; analysts predict the market growth of 10%
per year in all segments during the period from
"Osteros Biomedica" has the global IP rights for
2010 to 2018, and 3-4 % per year after 2018 when
MBC-11. Current IP consists of two U.S. patents, as
well as a European and a Canadian patent.
Product and technology
MBC-11 is chemically synthesized unique conjugate
of two molecules (etidronate and cytarabine)
designed for treatment of multiple myeloma,
osteosarcoma, as well as metastatic bone lesions.
The mechanism of action of this drug is based on
KC Health Coordinator for the UK Beagle Clubs The condition is seen in other breeds of dog too but Beagles along with Bernese Mountain Dogs, Duck Tolling Retrievers and Springer Spaniels seem to be over-represented in the canine population. It is primarily a disease of the younger dog, most often being seen around 6-8months of age for the first time although it has been seen as young as 10 weeks
APPLICATION Applicant's Name _________________ _________________ __________________ (please print) ____________________________________________________________________ City ___________________________ State _________________ Country ________________________ Mailing Address (if different than above) ___________________________________________________ _________________________
Company Overview